title: Fine-tuning risk assessment with antiepileptic drug use in pregnancy.
authors.affiliation: ManchesterLiverpool, UKStanford, CAManchester, UK.
authors.forename: George
authors.initials: G
authors.lastname: Mawer
authors.affiliation: Manchester.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Bromley
authors.affiliation: Liverpool, UK.
authors.forename: Gus A
authors.initials: GA
authors.lastname: Baker
authors.affiliation: Stanford, CA.
authors.forename: Kimford J
authors.initials: KJ
authors.lastname: Meador
authors.affiliation: Manchester, UK.
authors.forename: Jill
authors.initials: J
authors.lastname: Clayton-Smith
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects*; D002220:Carbamazepine / Q000009:adverse effects*; D002657:Child Development / Q000187:drug effects*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007360:Intelligence / Q000187:drug effects*; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced*; D014227:Triazines / Q000009:adverse effects*; D014635:Valproic Acid / Q000009:adverse effects*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D002220:Carbamazepine; D014635:Valproic Acid